INTERVIEW: Oncology central as Takeda extends global reach
This article was originally published in Scrip
Takeda has been positioning oncology as a major area of investment and growth since its $8.8bn acquisition of the US firm Millennium in 2008, with expectations that a stronger presence would help it face the loss of exclusivity for blockbuster antidiabetic Actos (pioglitazone) and bolster its presence in a critical therapeutic area.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.